Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Will the real multiple sclerosis please stand up?
Individual Neuronal Subtypes Exhibit Diversity in CNS Myelination Mediated by Synaptic Vesicle Release.
Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis.
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Daytime sleepiness versus fatigue in patients with multiple sclerosis: A systematic review on the Epworth sleepiness scale as an assessment tool.
The 10th European Congress of Neuropathology
Clinically isolated syndromes.
Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids.
Potassium channel KIR4.1 as an immune target in multiple sclerosis.
Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
Perk Ablation Ameliorates Myelination in S63del-Charcot-Marie-Tooth 1B Neuropathy.
Accumulation and therapeutic modulation of 6-sulfo LacNAc(+) dendritic cells in multiple sclerosis.
Differential transcriptional response profiles in human myeloid cell populations.
Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis ((DECIDE))
A monoclonal natural human IgM protects axons in the absence of remyelination.
Sex hormones and multiple sclerosis: another informative failure.
European Medicines Agency accepts Marketing Authorization Application for conditional approval of masitinib in the treatment of pancreatic cancer
CHMP issues positive opinion for TECFIDERA™ (dimethyl fumarate) as a first-line treatment for multiple sclerosis in the European Union
Predictors of long-term disability accrual in relapse-onset multiple sclerosis.
Overview of the immune system.
Neuroimmunology: Clostridium-reactive T cells are implicated in the pathogenesis of neuromyelitis optica.
Nephrotic-range proteinuria on interferon-β treatment: immune-induced glomerulonephritis or other pathway?
Pattern of remyelination in the CNS.
Teriflunomide
Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder.
Pages
« first
‹ previous
…
72
73
74
75
76
77
78
79
80
…
next ›
last »